On March 26, 2014, BioTime, Inc. (NYSEMKT:BTX) entered into an amendment to our Controlled Equity Offering SM Sales Agreement, dated August 24, 2012 with Cantor Fitzgerald & Co. that provides for the issuance and sale by us of additional common shares having an aggregate offering price of up to $15,000,000. BioTime, Inc. (NYSEMKT:BTX) shares after opening at $3.25 moved to $3.32 on last trade day and at the end of the day closed at $3.24. Company price to sales ratio in past twelve months was calculated as 41.43 and price to cash ratio as 33.15. BioTime, Inc. (NYSEMKT:BTX) showed a negative weekly performance of -7.69%.
On March 13, 2014, Celsion Corporation(NASDAQ:CLSN) issued a press release reporting its financial results for the year ended December 31, 2013. Celsion Corporation (NASDAQ:CLSN) shares advanced 2.06% in last trading session and ended the day on $3.46. CLSN return on equity ratio is recorded as -65.00% and its return on assets is -40.30%. Celsion Corporation (NASDAQ:CLSN) yearly performance is -26.85%.
Atossa Genetics, Inc. (NASDAQ:ATOS) announced 2013 financial results and provided an update on recent corporate developments. Atossa Genetics Inc. (NASDAQ:ATOS) shares moved down -3.41% in last trading session and was closed at $1.70, while trading in range of $1.67 – $1.75. Atossa Genetics Inc. (NASDAQ:ATOS) year to date (YTD) performance is -26.72%.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) on march 18 Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) weekly performance is -18.65%. On last trading day company shares ended up $10.93. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) distance from 50-day simple moving average (SMA50) is -19.46%.